ID   HL-60/RS
AC   CVCL_XE38
DR   cancercelllines; CVCL_XE38
DR   CCRID; 4201PAT-CCTCC00581
DR   Wikidata; Q94211650
RX   Patent=CN104004715B;
RX   PubMed=29399180;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201430.
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0002 ! HL-60
SX   Female
AG   36Y
CA   Cancer cell line
DT   Created: 06-09-19; Last updated: 05-10-23; Version: 10
//
RX   Patent=CN104004715B;
RA   Wei H.-L., Chen J., Cheng J., Xie B., Yi J., Wang B.;
RT   "Human leukemia HL-60 cell drug-resistance cell line HL-60/RS cell and
RT   preparation method thereof.";
RL   Patent number CN104004715B, 16-Nov-2016.
//
RX   PubMed=29399180; DOI=10.3892/ol.2017.7353;
RA   Chen J., Wei H.-L., Cheng J., Xie B., Wang B., Yi J., Tian B.-Y.,
RA   Liu Z., Wang F.-F., Zhang Z.-W.;
RT   "Characteristics of doxorubicin-selected multidrug-resistant human
RT   leukemia HL-60 cells with tolerance to arsenic trioxide and
RT   contribution of leukemia stem cells.";
RL   Oncol. Lett. 15:1255-1262(2018).
//